Home Equities Score Nabriva Therapeutics PLC (NBRV) Stock Skyrockets Following Disclosure of Highly Promising Topline...

Nabriva Therapeutics PLC (NBRV) Stock Skyrockets Following Disclosure of Highly Promising Topline Data Results

Nabriva Therapeutics PLC (NBRV) stock prices were down by a marginal 0.67% as of the market closing on May 25th, 2021, bringing the price per share down to USD$1.48 at the end of the trading day. Subsequent pre-market fluctuations saw the stock skyrocket by 45.27%, bringing it up to USD$2.15.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Positive Topline Results

The company announced on May 25th, 2021 that it had achieved positive topline results from Phases 3 of Sinovant’s bridging study of Lefamulin in Chinese adults with community-acquired bacterial pneumonia (CAPB). The multi-center, randomized, double-blind trial was used to evaluate the safety and efficacy of IV to oral lefamulin compared to moxifloxacin in 125 subjects with CAPB.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

Read More

Clinical Study

The study randomized subjects with two patients being administered Lefamulin for every patient-administered moxifloxacin. The subjects were stratified according to previous antibiotic exposure, pneumonia severity index (PSI) risk class, and renal impairment. Drugs throughout the study were dosed in a double-dummy double-blinded fashion.

Results of Clinical Study

Lefamulin reported achieving its primary endpoint of non-inferiority vs moxifloxacin for IACR-TOC in the mITT population. The success rate of Lefamulin at 76.8% being higher than the 71.4% reported for moxifloxacin is evidence of the success of the study, with the findings being consistent across subgroups. In regard to the key secondary endpoint of IACR-TOC in the CE population, success rates for lefaulin were 86% and moxifloxacin reported a success rate of 86.2%. These results reflect the results of the global Phase 3 LEAP 1 and LEAP 2 clinical trials conducted by NBRV.

Potential of Lefamulin

Consolidating previous findings, Lefamulin was observed to be generally safe and well-tolerated. Overall rate of treatment-emergent adverse events (TAEAs) were found to be compared to that of moxifloxacin. An overwhelming majority of TAEAs in both Lefamulin and moxifloxacin arms ranged from mild to moderate severity. Serious adverse events (SAEs) occurred in 4% patients treated with lefamulin and 10% occurred in moxifloxacin-treated patients. Only 5% of subjects reported TAEAs that resulted in discontinuation in either treatment arm.

Collaboration with Suzhou

Sinovant also entered into an agreement with Sumitomo Pharmaceuticals (Suzhou) Co., Ltd., with the aim of acquiring development and commercialization rights for Lefamulin in the Greater China region. As per the agreement, Sinovant will assign Suzhou its license agreement for Lefamulin. The completion of this transaction is contingent on certain conditions and is forecasted to occur in the second calendar quarter of 2021.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Future Outlook for NBRV

With the disclosure of the highly promising topline results from their clinical trial, NBRV is poised to push for the commercialization of its treatment. Current and potential investors are hopeful in the company’s ability to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Aprea Therapeutics Inc. (APRE) stock soars during current market trading. What’s the update?

Aprea Therapeutics Inc. (NASDAQ: APRE) stock gained by 41.03% at the last check in the current market trading. Aprea Therapeutics is a pharmaceutical business...

Roblox Corp. (NASDAQ: RBLX) stock falls during pre-market trading session. What’s happening?

Roblox Corp. (NASDAQ: RBLX) stock gained by 2.28% at last close while the RBLX stock price declines by 8.13% in the pre-market trading session....

Can-Fite BioPharma Inc. (CANF) stock soars during current market. Why so?

Can-Fite BioPharma Inc. (NASDAQ: CANF) stock gained by 4.42% in the current market trading session. Can-Fite BioPharma Ltd. is a medication research company in...

UXIN stock surges during current market. Here’s to know why?

Uxin Ltd. (NASDAQ: UXIN) stock gains by 14.67% at last check during current market trading. In China, Uxin Limited is a prominent online used...

Opgen Inc. (OPGN) stock surged during pre-market session. What’s driving it high?

Opgen Inc. (NASDAQ: OPGN) stock declined by 1.84% at the last close whereas the OPGN stock price gains by 22.07% in the pre-market trading...

Aprea Therapeutics Inc. (APRE) stock soars during current market trading. What’s the update?

Aprea Therapeutics Inc. (NASDAQ: APRE) stock gained by 41.03% at the last check in the current market trading. Aprea Therapeutics is a pharmaceutical business...

TAL Education Group (TAL) stock is tumbling today: What’s Going on?

Shares of the TAL Education Group (TAL) stock were tumbling in the current market trading session today on June 16, 2021, without any obvious...

SPI Energy Inc. (SPI) stock surged in the current market trading. Here’s the update

SPI Energy Inc. (NASDAQ: SPI) stock soars by 15.42% during the current market trading session. SPI Energy is an international renewable energy company that...

Related News

Ocugen Inc. (OCGN) stock surged during pre-market trading session. Here’s what you should know?

Ocugen Inc. (NASDAQ: OCGN) stock gained by 2.12% at last close while the OCGN stock price soars during pre-market trading by 4.95%. Ocugen, Inc....

Avenue Therapeutics Inc. (ATXI) stock plunged during pre-market trading. What’s behind this?

Avenue Therapeutics Inc. (NASDAQ: ATXI) stock declined by 28.27% at last close while the ATXI stock price falls during pre-market as well, by 8.94%....

Unique Fabricating Inc. (UFAB) stock gains during pre-market trading. Let’s figure out why?

Unique Fabricating Inc. (NASDAQ: UFAB) stock declined by 1.21% at the last close while the UFAB stock price tends to rise by 40.67% in...

Torchlight Energy Resources Inc. (TRCH) stock soars during after-hour session. Let’s see why?

Torchlight Energy Resources Inc. (NASDAQ: TRCH) stock gained by 14.74% at last close while the TRCH stock price further rose by 16.48% in the...

Orphazyme A/S (ORPH) stock is Popping High in Pre-Market today: Here’s to know Why?

Shares of Orphazyme A/S (ORPH) stock were popping high in the pre-market today on June 14, 2021, after dropping with more than half of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam